Arax Advisory Partners’s Pacira BioSciences PCRX Stock Holding History

Arax Advisory Partners’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$19.6K	Buy	+772	New	+$18.2K	﹤0.01%	3976
2026 Q1	–	Sell	-178	Closed	-$4.61K	–	4192
2025 Q4	$4.61K	Buy	+178	New	+$4.23K	﹤0.01%	2899
2024 Q4	–	Sell	-42	Closed	-$633	–	2662
2024 Q3	$633	Hold	42	–	–	﹤0.01%	2367
2024 Q2	$1.2K	Buy	+42	New	+$1.2K	﹤0.01%	2118

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Arax Advisory Partners's PCRX Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in Pacira BioSciences (PCRX) in Q2 2026: 772 shares worth $19.6K. The stake represents ﹤0.01% of the portfolio and ranks #3976 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in PCRX as recently as Q4 2025.

Arax Advisory Partners first reported a position in PCRX in Q2 2024 and has held it in 4 quarters since. 254 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

Arax Advisory Partners held 772 shares of Pacira BioSciences worth $19.6K as of Q2 2026.
Pacira BioSciences was a new Arax Advisory Partners position in Q2 2026.
Pacira BioSciences made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #3976 holding.
Arax Advisory Partners first reported a position in Pacira BioSciences in Q2 2024 and has held it in 4 quarters since.
254 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.